ArticleScientific reports2019
Role of biomarkers as predictors of acute kidney injury and mortality in decompensated cirrhosis.
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 3 syntheses or guidelines pooled it, 51 citations in OpenAlex.
- Mortality of Acute Kidney Injury in Cirrhosis: A Systematic Review and Meta-Analysis of Over 5 Million Patients Across Different Clinical Settings.Alimentary pharmacology & therapeutics · 2025Pooled it
- Association of Cystatin C Level with All-cause Mortality in Patients with Liver Cirrhosis: A Meta-analysis.Current medicinal chemistry · 2024Pooled it
- Impact of acute kidney injury on the risk of mortality in patients with cirrhosis: a systematic review and meta-analysis.Renal failure · 2022Pooled it
- Predictors of In-Hospital Mortality and Incomplete Kidney Recovery in Patients with Cirrhosis-Associated Non-Hepatorenal Syndrome Acute Kidney Injury: A Single-Center Retrospective Cohort Study.Journal of clinical medicine · 2026Article
- Renal Dysfunction and Serum Sodium-Based Risk Stratification for In-Hospital Mortality in Liver Cirrhosis.Medicina (Kaunas, Lithuania) · 2026Article
- Renal R2* as a noninvasive predictor of hepatorenal syndrome-acute kidney disease in cirrhotic patients with ascites: a retrospective cohort study.Quantitative imaging in medicine and surgery · 2026Article
- Clinical diagnosis and biomarkers of acute kidney injury in liver cirrhosis: a systematic review.Therapeutic advances in gastroenterology · 2026Review
- Tracking the trajectory of kidney dysfunction in cirrhosis: the acute kidney injury: chronic kidney disease spectrum.Clinical and molecular hepatology · 2025Review
- Understanding acute kidney injury in cirrhosis: Current perspective.World journal of hepatology · 2025Review
- The role of urinary biomarkers in the diagnosis of acute kidney injury in patients with liver cirrhosis.Scientific reports · 2025Article
- Article
- Reliability of neutrophil gelatinase-associated lipocalin in detecting acute tubular necrosis in decompensated cirrhosis: Systematic review and meta-analysis.World journal of hepatology · 2024Article
- Acute kidney injury in patients with cirrhosis: Acute Disease Quality Initiative (ADQI) and International Club of Ascites (ICA) joint multidisciplinary consensus meeting.Journal of hepatology · 2024Review
- Seeing and Sensing the Hepatorenal Syndrome (HRS): The Growing Role of Ultrasound-Based Techniques as Non-Invasive Tools for the Diagnosis of HRS.Diagnostics (Basel, Switzerland) · 2024Review
- Prediction models combining zonulin, LPS, and LBP predict acute kidney injury and hepatorenal syndrome-acute kidney injury in cirrhotic patients.Scientific reports · 2023Article
- Acute Kidney Injury in Liver Cirrhosis.Diagnostics (Basel, Switzerland) · 2023Review
- Urine neutrophil gelatinase-associated lipocalin as a biomarker of acute kidney injury and prognosis in decompensated chronic liver disease: A prospective study.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2023Article
- Development of a nomogram for the prediction of acute kidney injury after liver transplantation: a model based on clinical parameters and postoperative cystatin C level.Annals of medicine · 2023Article
- Soluble suppression of tumorigenicity 2 is a potential predictor of post-liver transplant renal outcomes.PloS one · 2023Article
- Acute kidney injury defined by cystatin C may be superior for predicting the outcomes of liver cirrhosis with acute gastrointestinal bleeding.Renal failure · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Evidence suggests that novel biomarkers predict acute kidney injury (AKI) development and outcome earlier than serum creatinine. The aim of this study was to determine the incidence and prognosis of AKI in decompensated cirrhotic patients, and also assess the usefulness of plasma cystatin C, urine neutrophil gelatinase associated lipocalin (NGAL), tissue inhibitor of metalloproteinase-2 (TIMP-2) and insulin-like growth factor-binding protein 7 (IGFBP7) in early prediction of AKI and mortality. Single-center, prospective observational study enrolling decompensated cirrhotic patients without AKI at the time of admission. Of 111 patients with decompensated cirrhosis, 45 (40.5%) developed AKI while hospitalized. Even with 53.3% being transient (stage 1), mortality was significantly higher in AKI than non-AKI patients (46.5% vs. 25%, p = 0.02). Plasma cystatin C and urine NGAL, but not urine [TIMP-2]·[IGFBP7] at the time of admission were found to be independent early predictors of AKI. Substitution of cystatin C for creatinine significantly improved the model for end-stage liver disease (MELD) score accuracy for mortality prediction. The incidence of AKI is high and is associated with high mortality in decompensated cirrhotic patients. Plasma cystatin C and urine NGAL are useful for early detection of AKI. MELD-cystatin C, rather than original MELD, improves predictive accuracy of mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.